Literature DB >> 28053374

Ang-1 and Ang-2 expression in angiomyolipoma and PEComa family tumors.

Swati Shrestha1, Carolyn Meyers2, Jia Shen1, Paulina Giacomelli1, Michelle A Scott3, Chia Soo4, Sarah M Dry2, Kang Ting1, Aaron W James5.   

Abstract

OBJECTIVE: Perivascular epithelioid cell tumors (PEComa) are an uncommon family of soft tissue tumors. Previously, we described that the presence of pericyte antigens among PEComa family tumors differs extensively by histologic appearance.
METHODS: Here, we extend our findings using the pericyte antigens Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2), using immunohistochemical detection in human tumor samples.
RESULTS: While Ang-1 showed no expression across any PEComa family tumor, Ang-2 showed expression that like other pericyte markers was largely determined by cytologic appearance. CONCLUSION/IMPLICATIONS: Pericytic marker expression in PEComa may represent a true pericytic cell of origin, or alternatively aberrant pericyte marker adoption.

Entities:  

Keywords:  Angiomyolipoma; Angiopoietin; Lymphangiomyoma; PEComa; Pericyte; Perivascular epithelioid cell tumor

Year:  2016        PMID: 28053374      PMCID: PMC5196089          DOI: 10.1016/j.jor.2016.12.001

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  20 in total

Review 1.  Endothelial/pericyte interactions.

Authors:  Annika Armulik; Alexandra Abramsson; Christer Betsholtz
Journal:  Circ Res       Date:  2005-09-16       Impact factor: 17.367

Review 2.  Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.

Authors:  Andrew L Folpe; Thomas Mentzel; Hans-Anton Lehr; Cyril Fisher; Bonnie L Balzer; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

3.  Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney.

Authors:  M Pea; F Bonetti; G Zamboni; G Martignoni; M Riva; R Colombari; A Mombello; M Bonzanini; A Scarpa; C Ghimenton
Journal:  Pathology       Date:  1991-07       Impact factor: 5.306

Review 4.  PEComa: what do we know so far?

Authors:  J L Hornick; C D M Fletcher
Journal:  Histopathology       Date:  2006-01       Impact factor: 5.087

5.  Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.

Authors:  Sandra P D' Angelo; Michelle R Mahoney; Brian A Van Tine; Douglas R Adkins; Maria T Grosse Perdekamp; Mercedes M Condy; Jason J Luke; Eliza Woodward Hartley; Cristina R Antonescu; William D Tap; Gary K Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-12       Impact factor: 3.333

6.  Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy.

Authors:  Fadi Brimo; Brian Robinson; Charles Guo; Ming Zhou; Matthieu Latour; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2010-05       Impact factor: 6.394

Review 7.  Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.

Authors:  Khalid Al Wadi; Prafull Ghatage
Journal:  Expert Opin Pharmacother       Date:  2016-03-21       Impact factor: 3.889

8.  Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

Authors:  Beverly L Falcón; Hiroya Hashizume; Petros Koumoutsakos; Jeyling Chou; James V Bready; Angela Coxon; Jonathan D Oliner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

9.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

Authors:  Michele De Palma; Mary Anna Venneri; Rossella Galli; Lucia Sergi Sergi; Letterio S Politi; Maurilio Sampaolesi; Luigi Naldini
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

10.  Pericytic mimicry in well-differentiated liposarcoma/atypical lipomatous tumor.

Authors:  Jia Shen; Swati Shrestha; P Nagesh Rao; Greg Asatrian; Michelle A Scott; Vi Nguyen; Paulina Giacomelli; Chia Soo; Kang Ting; Fritz C Eilber; Bruno Peault; Sarah M Dry; Aaron W James
Journal:  Hum Pathol       Date:  2016-04-08       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.